SIRPα's interaction with CD47 is crucial in the context of cancer because many tumor cells overexpress CD47 to evade the immune system. By signaling through SIRPα, these tumor cells inhibit macrophage-mediated phagocytosis, allowing them to escape immune surveillance and grow uncontrollably. This makes the SIRPα-CD47 axis a significant target for cancer immunotherapy.
